New siRNA drug aims to reverse liver damage in NASH patients
NCT ID NCT06322628
First seen Mar 16, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tests an experimental drug called VSA006 in 48 Chinese adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. The drug uses siRNA technology to lower a protein linked to liver damage. The goal is to see if VSA006 can improve liver scarring and inflammation without making the disease worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgeng Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.